<?xml version="1.0" encoding="UTF-8"?><!-- generator="bbPress" -->

<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
>

<channel>
<title>pharmaphorum forums &#187; Recent Posts</title>
<link>http://www.pharmaphorum.com/forums/</link>
<description>Bringing Healthcare Together</description>
<language>en</language>
<pubDate>Sun, 05 Feb 2012 03:06:48 +0000</pubDate>

<item>
<title>News on "As blockbuster drugs fade, so does TV advertising"</title>
<link>http://www.pharmaphorum.com/forums/topic/as-blockbuster-drugs-fade-so-does-tv-advertising#post-4327</link>
<pubDate>Fri, 03 Feb 2012 16:53:52 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4327@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;The DTC juggernaut is weakening. As The New York Times reports, industry spending on TV ads fell by 2% in 2011, the fourth consecutive year of decline. Altogether, TV spending is down 20% from 2007 levels. While it's quite a turnabout from the run-up in...&#60;/p&#62;
&#60;p&#62;Source: FiercePharma&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzxtm6l8lbxml2lbxll2xmm6lzlbl8mblzxtzblhlolnltz8lmzozxzlzxlzzxzhzhlmzhztlozoloztzozzzmzhzmzxznznztz2zzzmz2ltlozzzhl2ztzhznllzlz2z2ztlmzxzlmllzlbz8llzezezezezezezezeztzmzhzexzm8zozzztzxznztztznzt&#38;amp;a=znzxzzznzozhzezxzoze&#38;amp;f=tmlklblx&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "AZ cuts do not put UK life sciences sector at risk - ABPI"</title>
<link>http://www.pharmaphorum.com/forums/topic/az-cuts-do-not-put-uk-life-sciences-sector-at-risk-abpi#post-4326</link>
<pubDate>Fri, 03 Feb 2012 16:50:21 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4326@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Reaction to AstraZeneca's announcement that some 7,300 jobs would be axed by the end of 2014 has continued, and it seems that the firm's UK research staff will be reduced by 250-350 posts. The company has not given many specifics regarding the...&#60;/p&#62;
&#60;p&#62;Source: Pharma Times&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhzlzezezozhzezlzhmlxaz8zozmz2zezmztzhzlzxzl&#38;amp;a=z2zhzlzezezozhzezlzh&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Merck KGaA signs $550 million cancer pact with Threshold"</title>
<link>http://www.pharmaphorum.com/forums/topic/merck-kgaa-signs-550-million-cancer-pact-with-threshold-1#post-4325</link>
<pubDate>Fri, 03 Feb 2012 16:42:02 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4325@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Merck KGaA has linked up with the USA's Threshold Pharmaceutical to co-develop and commercialise the latter's late-stage hypoxia-targeted drug for certain cancers. The drug, TH-302 is currently undergoing a Phase III clinical trial in patients with soft...&#60;/p&#62;
&#60;p&#62;Source: Pharma Times&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhzlzezezozhzezzzzmlxaz8zozmz2zezmztzhzlzxzt&#38;amp;a=z2zhzlzezezozhzezzzz&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Drug Shortages Cause Cancer Patients To Die Sooner"</title>
<link>http://www.pharmaphorum.com/forums/topic/drug-shortages-cause-cancer-patients-to-die-sooner#post-4323</link>
<pubDate>Fri, 03 Feb 2012 10:04:41 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4323@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;This may not come as a surprise, but the ongoing shortages of various prescription drugs - notably, injectables that are used to treat assorted cancers - are not only preventing patients from receiving timely or the most appropriate treatments, but...&#60;/p&#62;
&#60;p&#62;Source: Pharmalot&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzxtm6l8lbxml2lbxll2xmm6lzlbl8mblzxtzblhlolnltz8znllzoztltl2zxllzlzhltlllzl2z2lozozzzmzhzoznzlzmzxzxztzmzezozhllzmzlz2ltzezmzlzxlzztzxztllmllzlbz8llzezezezezezezezeztzmzhzexzm8zozzztzxznztztznzt&#38;amp;a=znzxzzzozhzezlzmzlzo&#38;amp;f=tmlklblx&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Gilead Sciences Announces Fourth Quarter and Full Year 2011 Financial Results"</title>
<link>http://www.pharmaphorum.com/forums/topic/gilead-sciences-announces-fourth-quarter-and-full-year-2011-financial-results#post-4322</link>
<pubDate>Fri, 03 Feb 2012 09:59:25 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4322@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Gilead Sciences, Inc. (Nasdaq:GILD) announced today its results of operations for the fourth quarter and full year 2011. Total revenues for the fourth quarter of 2011 increased 10 percent to $2.20 billion, from $2.00 billion for the fourth quarter of...&#60;/p&#62;
&#60;p&#62;Source: BioSpace&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhz2z2znzlzlznzxzmmlxaz8zozmz2zezmztzhzxzxzx&#38;amp;a=z2zhz2z2znzlzlznzxzm&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Czechs beef up investment in biotech research"</title>
<link>http://www.pharmaphorum.com/forums/topic/czechs-beef-up-investment-in-biotech-research#post-4321</link>
<pubDate>Fri, 03 Feb 2012 09:57:02 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4321@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;The Czech Republic is substantially boosting its investment in biotechnology research, with plans to build a massive research center near Prague set to employ 600 people, the Prague Daily Monitor is reporting. Plans call for spending 2.4 billion crowns...&#60;/p&#62;
&#60;p&#62;Source: FierceBiotech&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhz2zlztzozzzmz2ztmlxaz8zozmz2zezmztzhzlzlz2&#38;amp;a=z2zhz2zlztzozzzmz2zt&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Novo amps up 2012 expectations on strong Victoza sales"</title>
<link>http://www.pharmaphorum.com/forums/topic/novo-amps-up-2012-expectations-on-strong-victoza-sales#post-4320</link>
<pubDate>Fri, 03 Feb 2012 09:51:47 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4320@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Novo Nordisk ( $NVO ) boosted its sales outlook for 2012 after sales of the diabetes drug Victoza more than doubled to 2.1 billion crowns, beating analyst estimates. It's counting on new long-acting insulins that are awaiting approval to help it compete...&#60;/p&#62;
&#60;p&#62;Source: FiercePharma&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhz2zxzzzmznztzxzomlxaz8zozmz2zezmztzhzlzxzl&#38;amp;a=z2zhz2zxzzzmznztzxzo&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "GlaxoSmithKline (GSK) Settles 20,000 Lawsuits Over Avandia, Lawyer Says"</title>
<link>http://www.pharmaphorum.com/forums/topic/glaxosmithkline-gsk-settles-20000-lawsuits-over-avandia-lawyer-says#post-4319</link>
<pubDate>Fri, 03 Feb 2012 09:14:26 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4319@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;GlaxoSmithKline Plc (GSK), which is paying $3 billion to resolve government claims that it illegally marketed drugs such as the Avandia diabetes medication, agreed to settle more lawsuits over the pills, a lawyer said. Glaxo, the U.K.âs biggest drugmaker...&#60;/p&#62;
&#60;p&#62;Source: BioSpace&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhz2zhzezzzzzezzzemlxaz8zozmz2zezmztzhzlzlz2&#38;amp;a=z2zhz2zhzezzzzzezzze&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "The Pfizer Generation: Who Pays For The Babies?"</title>
<link>http://www.pharmaphorum.com/forums/topic/the-pfizer-generation-who-pays-for-the-babies#post-4318</link>
<pubDate>Thu, 02 Feb 2012 16:47:09 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4318@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;About nine months from now, a new phenomenon may appear at a hospital near you: the Pfizer baby. Why? The drugmaker has taken the embarrassing step of recalling 1 million packets of birth control pills due to a packaging error. Some blister packs may...&#60;/p&#62;
&#60;p&#62;Source: Pharmalot&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzxtm6l8lbxml2lbxll2xmm6lzlbl8mblzxtzblhlolnltz8znl2znzxzoz2zmzxzhzezxzlzxzxzlzozozzzmzhzoznzmz2z2zmzlznzollztztlmzezmzezolmlmznz2ztz2lzzemllzlbz8llzezezezezezezezeztzmzhzexzm8zozzztzxznztztznzt&#38;amp;a=znzxzzzoztz2z2zzz2zn&#38;amp;f=tmlklblx&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Merck Announces Full-Year and Fourth-Quarter 2011 Financial Results"</title>
<link>http://www.pharmaphorum.com/forums/topic/merck-announces-full-year-and-fourth-quarter-2011-financial-results#post-4317</link>
<pubDate>Thu, 02 Feb 2012 16:35:55 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4317@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2011...&#60;/p&#62;
&#60;p&#62;Source: BioSpace&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhz2zmzxztzoznztzomlxaz8zozmz2zezmztzhzxzxzx&#38;amp;a=z2zhz2zmzxztzoznztzo&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "EU Commission tells Italy: &#34;comply with rules on generics&#34;"</title>
<link>http://www.pharmaphorum.com/forums/topic/eu-commission-tells-italy-comply-with-rules-on-generics#post-4316</link>
<pubDate>Thu, 02 Feb 2012 16:33:52 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4316@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;The European Commission has given Italy two months to comply with European Union (EU) rules concerning the provision of marketing authorisations (MA) for generic drugs. Italy's Intellectual Property Code contains an article which links the MA process to...&#60;/p&#62;
&#60;p&#62;Source: Pharma Times&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhz2zmzhzozxzxzhzlmlxaz8zozmz2zezmztzhzlzxzl&#38;amp;a=z2zhz2zmzhzozxzxzhzl&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Universal flu vaccine might be step closer"</title>
<link>http://www.pharmaphorum.com/forums/topic/universal-flu-vaccine-might-be-step-closer#post-4315</link>
<pubDate>Thu, 02 Feb 2012 16:30:11 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4315@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Did you get the flu last year? Unfortunately, that won't stop you getting it this year, or next year, or whenever bird flu or swine flu next strikes, because the virus mutates so rapidly. This means that the flu vaccine has to be made each year, based on...&#60;/p&#62;
&#60;p&#62;Source: FierceVaccines&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhz2zzzezezmzhzmzhmlxaz8zozmz2zezmztzhzlzxzl&#38;amp;a=z2zhz2zzzezezmzhzmzh&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Analysis: Pharmaceutical woes"</title>
<link>http://www.pharmaphorum.com/forums/topic/analysis-pharmaceutical-woes#post-4314</link>
<pubDate>Thu, 02 Feb 2012 16:21:31 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4314@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;The announcement by the drug maker AstraZeneca that it will cut another 7,300 jobs is the latest warning about the health of the pharmaceutical industry. It comes a year after . There are still large profits being made, but there are pressures on the...&#60;/p&#62;
&#60;p&#62;Source: BBC&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhz2zzzlzezzz2z2zomlxaz8zozmz2zezmztzhzlzxzl&#38;amp;a=z2zhz2zzzlzezzz2z2zo&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Lubiprostone Meets Primary Endpoint in Phase 3 Clinical Trial for Opioid-Induced Bowel Dysfunction"</title>
<link>http://www.pharmaphorum.com/forums/topic/lubiprostone-meets-primary-endpoint-in-phase-3-clinical-trial-for-opioid-induced-bowel-dysfunction#post-4313</link>
<pubDate>Thu, 02 Feb 2012 10:34:13 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4313@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Aim to File for Approval of Lubiprostone as First Oral Drug for Prescription-based Treatment of OBD Anticipate sNDA Filing in US in First Half of 2012 Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) and Takeda Pharmaceuticals U.S.A., Inc. announced...&#60;/p&#62;
&#60;p&#62;Source: Reuters&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhz2zoz2zxz2zzzezomlxaz8zozmz2zezmztzhzxzxzx&#38;amp;a=z2zhz2zoz2zxz2zzzezo&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "AstraZeneca axes 7,300 jobs as growth stalls"</title>
<link>http://www.pharmaphorum.com/forums/topic/astrazeneca-axes-7300-jobs-as-growth-stalls#post-4312</link>
<pubDate>Thu, 02 Feb 2012 10:30:55 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4312@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;AstraZeneca is cutting a further 7,300 jobs and expects earnings to fall this year as patents on key drugs expire and governments in Europe and the United States squeeze prices. Britain's second-biggest drugmaker said on Thursday the latest phase of cost...&#60;/p&#62;
&#60;p&#62;Source: Reuters&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhz2zozxzeznz2zozemlxaz8zozmz2zezmztzhzlzxzl&#38;amp;a=z2zhz2zozxzeznz2zoze&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Pakistan drug manufacturers make plea for oversight"</title>
<link>http://www.pharmaphorum.com/forums/topic/pakistan-drug-manufacturers-make-plea-for-oversight#post-4311</link>
<pubDate>Thu, 02 Feb 2012 08:06:19 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4311@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;In many countries, asking for more regulation of the pharmaceutical industry would seem like asking for trouble. But not in Pakistan, where a drug manufacturing scandal involving the deaths of more than 130 patients and the sickening of hundreds more has...&#60;/p&#62;
&#60;p&#62;Source: FiercePharmaManufacturing&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzxtm6l8lbxml2lbxll2xmm6lzlbl8mblzxtzblhlolnltz8znznztlmz2znzllllllllmzhloltzolozozzzmzhzozlzez2ztznzezlzezxzzzoztzxzmzezlltztzxzlztltlmlzmllzlbz8llzezezezezezezezeztzmzhzexzm8zozzztzxznztztznzt&#38;amp;a=znzxzmzhzlzzzezhzmzt&#38;amp;f=tmlklblx&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Medivation, Inc. Soars as Prostate Cancer Drug is Well-tolerated in Phase 3 Trial"</title>
<link>http://www.pharmaphorum.com/forums/topic/medivation-inc-soars-as-prostate-cancer-drug-is-well-tolerated-in-phase-3-trial#post-4310</link>
<pubDate>Thu, 02 Feb 2012 07:59:13 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4310@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) announced positive results on all efficacy endpoints from the Phase 3 AFFIRM trial of the investigational drug MDV3100 in men with prostate cancer previously treated with chemotherapy....&#60;/p&#62;
&#60;p&#62;Source: BioSpace&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhztznzzztzzzzzmzmmlxaz8zozmz2zezmztzhzlzlz2&#38;amp;a=z2zhztznzzztzzzzzmzm&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "No need to loosen conflict rules, U.S. FDA head says"</title>
<link>http://www.pharmaphorum.com/forums/topic/no-need-to-loosen-conflict-rules-us-fda-head-says#post-4309</link>
<pubDate>Thu, 02 Feb 2012 07:55:19 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4309@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Congress should not loosen conflict of interest rules to expand the pool of potential U.S. government health advisers, the head of the Food and Drug Administration said on Wednesday. Lawmakers had proposed bills that...&#60;/p&#62;
&#60;p&#62;Source: Reuters&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhztznz2zzznzmznzxmlxaz8zozmz2zezmztzhzlzxzt&#38;amp;a=z2zhztznz2zzznzmznzx&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Cancer drug &#039;too expensive for NHS&#039;"</title>
<link>http://www.pharmaphorum.com/forums/topic/cancer-drug-too-expensive-for-nhs#post-4308</link>
<pubDate>Thu, 02 Feb 2012 07:43:33 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4308@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Experts call watchdog's decision on abiraterone a huge blow to men with late-stage prostate cancer A drug hailed as a breakthrough in extending the lives of men with late-stage prostate cancer is too expensive for use on the NHS, a watchdog said on...&#60;/p&#62;
&#60;p&#62;Source: The Guardian&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhz2zozozlzozxzmzomlxaz8zozmz2zezmztzhzlzlz2&#38;amp;a=z2zhz2zozozlzozxzmzo&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Pfizer recalls 1 million packets of US birth control pills"</title>
<link>http://www.pharmaphorum.com/forums/topic/pfizer-recalls-1-million-packets-of-us-birth-control-pills#post-4307</link>
<pubDate>Wed, 01 Feb 2012 18:11:14 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4307@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;US pharmaceutical giant Pfizer on Tuesday recalled one million packets of birth control pills over a packaging error that could put women at risk of unintended pregnancy...&#60;/p&#62;
&#60;p&#62;Source: Yahoo! Health News&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzxtm6l8lbxml2lbxll2xmm6lzlbl8mblzxtzblhlolnltz8loztzmzhz2z2znzozxlzlmllzxlzlml2zozzzmzhzozozmzmzzzmztztzezozzlzlzzhltlollzhzhlozeztltlmzzmllzlbz8llzezezezezezezezeztzmzhzexzm8zozzztzxznztztznzt&#38;amp;a=znzxzmzzzoznzhztzzzn&#38;amp;f=tmlklblx&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer"</title>
<link>http://www.pharmaphorum.com/forums/topic/savient-pharmaceuticals-appoints-david-y-norton-interim-chief-executive-officer#post-4306</link>
<pubDate>Wed, 01 Feb 2012 18:04:02 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4306@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Pre-Announces Range of KRYSTEXXA® Net Sales for Fourth Quarter 2011 EAST BRUNSWICK, N.J., Feb. 1, 2012  /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the Company's Board of Directors has appointed David Y. Norton, a...&#60;/p&#62;
&#60;p&#62;Source: BioSpace&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhztz2zlz2ztzoz2zzmlxaz8zozmz2zezmztzhzlzxzt&#38;amp;a=z2zhztz2zlz2ztzoz2zz&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Dendreon Announces CEO and Chairman Succession Plan"</title>
<link>http://www.pharmaphorum.com/forums/topic/dendreon-announces-ceo-and-chairman-succession-plan#post-4305</link>
<pubDate>Wed, 01 Feb 2012 18:02:49 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4305@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;– Dendreon Corporation (Nasdaq: DNDN) today announced that its Board of Directors has elected John H. Johnson to the position of president and chief executive officer (CEO), to succeed Mitchell H. Gold, MD, who has served as president and CEO for nearly a...&#60;/p&#62;
&#60;p&#62;Source: BioSpace&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhztz2zxzzzmznzxzxmlxaz8zozmz2zezmztzhzlzxzt&#38;amp;a=z2zhztz2zxzzzmznzxzx&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Roche places bets on new products for 2012 growth"</title>
<link>http://www.pharmaphorum.com/forums/topic/roche-places-bets-on-new-products-for-2012-growth#post-4304</link>
<pubDate>Wed, 01 Feb 2012 18:00:39 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4304@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Roche’s 2011 earnings may have experienced a 4% drop but the company is remaining optimistic about growth in the new year as new products flood onto the market. The Swiss drugmaker posted a 4% drop in core earnings per share to 12.30 Swiss francs when it...&#60;/p&#62;
&#60;p&#62;Source: Pharma Times&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhztzlztzhztzzzhzomlxaz8zozmz2zezmztzhzlzxzl&#38;amp;a=z2zhztzlztzhztzzzhzo&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Sanofi trims staff at Genzyme R&#38;D as it builds Boston hub"</title>
<link>http://www.pharmaphorum.com/forums/topic/sanofi-trims-staff-at-genzyme-rd-as-it-builds-boston-hub#post-4303</link>
<pubDate>Wed, 01 Feb 2012 17:53:34 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4303@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;A year after closing on its $20 billion acquisition of Genzyme, the new powers that be at Sanofi ( $SNY ) have triggered a round of layoffs and relocations in the R&#38;amp;D wing of the business in Boston. There's no word on exactly how many research personnel...&#60;/p&#62;
&#60;p&#62;Source: FierceBiotech&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhztzlznzezmzzzozomlxaz8zozmz2zezmztzhzlzxzt&#38;amp;a=z2zhztzlznzezmzzzozo&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Vertex nabs expedited FDA OK on breakthrough CF drug"</title>
<link>http://www.pharmaphorum.com/forums/topic/vertex-nabs-expedited-fda-ok-on-breakthrough-cf-drug#post-4302</link>
<pubDate>Wed, 01 Feb 2012 08:17:42 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4302@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Vertex Pharmaceuticals ( $VRTX ) is no longer a one-trick biotech company. The FDA issued an early approval today for Kalydeco (ivacaftor), a new drug that promises to strengthen the lungs and ease symptoms for a slice of the patient population sharing a...&#60;/p&#62;
&#60;p&#62;Source: FierceBiotech&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhztzozezmzhz2zlz2mlxaz8zozmz2zezmztzhzlzlz2&#38;amp;a=z2zhztzozezmzhz2zlz2&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "WSJ: Another executive shake-up at J&#38;J&#039;s McNeil unit"</title>
<link>http://www.pharmaphorum.com/forums/topic/wsj-another-executive-shake-up-at-jjs-mcneil-unit#post-4301</link>
<pubDate>Wed, 01 Feb 2012 08:13:33 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4301@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Johnson &#38;amp; Johnson ( $JNJ ) is taking an eraser to its McNeil Consumer Healthcare org chart again. Less than 12 months after a management shake-up put them in positions crucial to a McNeil turnaround, group chairmen Patrick Mutchler and Pericles...&#60;/p&#62;
&#60;p&#62;Source: FiercePharma&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhztzozmztzxzlzzztmlxaz8zozmz2zezmztzhzlzxzl&#38;amp;a=z2zhztzozmztzxzlzzzt&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Sanger Institute survey tests waters on genomic data use"</title>
<link>http://www.pharmaphorum.com/forums/topic/sanger-institute-survey-tests-waters-on-genomic-data-use#post-4300</link>
<pubDate>Wed, 01 Feb 2012 08:10:41 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4300@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;The Wellcome Trust Sanger Institute, the genomics research centre based in Cambridge, UK, is launching a survey to gauge the views of the public on how genetic research information should be used and shared. The survey, which the Institute hopes will be...&#60;/p&#62;
&#60;p&#62;Source: Pharma Times&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhztzozhzhztzozeztmlxaz8zozmz2zezmztzhzlzxzl&#38;amp;a=z2zhztzozhzhztzozezt&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Pfizer profits battered as generic Lipitor hits US market"</title>
<link>http://www.pharmaphorum.com/forums/topic/pfizer-profits-battered-as-generic-lipitor-hits-us-market#post-4299</link>
<pubDate>Wed, 01 Feb 2012 08:02:21 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4299@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Pfizer has reported a 50% slump in net income for the fourth quarter to $1.44 billion, hurt by generic competition to the cholesterol blockbuster Lipitor. The drug giant's turnover came in at $16.75 billion, down 4%, while biopharmaceutical sales...&#60;/p&#62;
&#60;p&#62;Source: Pharma Times&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhztztzmztzhz2zozhmlxaz8zozmz2zezmztzhzxzxzx&#38;amp;a=z2zhztztzmztzhz2zozh&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "FDA approves Vertex cystic fibrosis drug Kalydeco "</title>
<link>http://www.pharmaphorum.com/forums/topic/fda-approves-vertex-cystic-fibrosis-drug-kalydeco%e2%80%a8#post-4298</link>
<pubDate>Wed, 01 Feb 2012 07:59:10 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4298@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;The US Food and Drug Administration has given the green light to Vertex Pharmaceuticals' Kalydeco for the treatment of a rare form of cystic fibrosis. The approval covers patients aged six and older who have the specific G551D mutation in the cystic...&#60;/p&#62;
&#60;p&#62;Source: Pharma Times&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhztztzmztzhz2zezmmlxaz8zozmz2zezmztzhzlzlz2&#38;amp;a=z2zhztztzmztzhz2zezm&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "J&#38;J Reorganizes Consumer Health Unit, Again"</title>
<link>http://www.pharmaphorum.com/forums/topic/jj-reorganizes-consumer-health-unit-again#post-4297</link>
<pubDate>Tue, 31 Jan 2012 18:06:36 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4297@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;For the second time in less than a year, Johnson &#38;amp; Johnson is overhauling leadership at its embattled consumer health unit, which has spawned an embarrassing and long-running scandal over a series of manufacturing gaffes. In the latest shift, the health...&#60;/p&#62;
&#60;p&#62;Source: Pharmalot&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzxtm6l8lbxml2lbxll2xmm6lzlbl8mblzxtzblhlolnltz8znzzzelzzezelozzzxzhzlzolzzxznzmzozzzmzhzezozxzhzezmztzmznz2zzlozllzzozmznlzzozmzeztltzhzxmllzlbz8llzezezezezezezezeztzmzhzexzm8zozzztzxznztztznzt&#38;amp;a=znzxzozmzzzezxzxzmzz&#38;amp;f=tmlklblx&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Abbott slashes 700 jobs"</title>
<link>http://www.pharmaphorum.com/forums/topic/abbott-slashes-700-jobs#post-4296</link>
<pubDate>Tue, 31 Jan 2012 18:03:15 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4296@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Abbott Laboratories has said it will cut 700 jobs across its US and Puerto Rican operations, including hundreds of manufacturing posts, despite posting sales and earnings growth in 2011. The announcement comes as Abbott gears up for a major reorganisation...&#60;/p&#62;
&#60;p&#62;Source: InPharm&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhzzzhzlzezzztz2ztmlxaz8zozmz2zezmztzhzlzlz2&#38;amp;a=z2zhzzzhzlzezzztz2zt&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "AngioDynamics to Acquire Navilyst Medical for $372 Million"</title>
<link>http://www.pharmaphorum.com/forums/topic/angiodynamics-to-acquire-navilyst-medical-for-372-million#post-4295</link>
<pubDate>Tue, 31 Jan 2012 18:00:12 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4295@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;AngioDynamics to host conference call today at 11:30 am ET Increases Scale in Vascular Access and Peripheral Vascular Markets Expands Product Portfolio and Adds Innovative Technologies Strengthens Focus on Operational Excellence Expected to be Accretive...&#60;/p&#62;
&#60;p&#62;Source: BioSpace&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhzzzhzlzlzhzhzozxmlxaz8zozmz2zezmztzhzlzlz2&#38;amp;a=z2zhzzzhzlzlzhzhzozx&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Valeant gives up on bid to buy Ista"</title>
<link>http://www.pharmaphorum.com/forums/topic/valeant-gives-up-on-bid-to-buy-ista#post-4294</link>
<pubDate>Tue, 31 Jan 2012 17:57:56 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4294@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Valeant Pharmaceuticals International has withdrawn its offer to acquire Ista Pharmaceuticals, a fortnight after upping its bid for the eye specialist. Just before Christmas, Valeant's $6.50 per share offer, which valued Ista at $314 million, was...&#60;/p&#62;
&#60;p&#62;Source: Pharma Times&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhzzzhznz2ztzhzxzxmlxaz8zozmz2zezmztzhzlzlz2&#38;amp;a=z2zhzzzhznz2ztzhzxzx&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "NHS reforms criticised by healthcare journals"</title>
<link>http://www.pharmaphorum.com/forums/topic/nhs-reforms-criticised-by-healthcare-journals#post-4293</link>
<pubDate>Tue, 31 Jan 2012 17:54:44 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4293@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;A trio of leading healthcare journals has come out against the government’s NHS reforms. The British Medical Journal is leading the denouncement alongside the Health Service Journal and its sister paper, the Nursing Times. In an editorial authored by the...&#60;/p&#62;
&#60;p&#62;Source: InPharm&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhztzezozxzzznzhzhmlxaz8zozmz2zezmztzhzlzxzl&#38;amp;a=z2zhztzezozxzzznzhzh&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>
<item>
<title>News on "Lilly (Eli) &#38; Co: Lilly Reports Fourth-Quarter and Full-Year 2011 Results"</title>
<link>http://www.pharmaphorum.com/forums/topic/lilly-eli-co-lilly-reports-fourth-quarter-and-full-year-2011-results#post-4292</link>
<pubDate>Tue, 31 Jan 2012 17:53:03 +0000</pubDate>
<dc:creator>News</dc:creator>
<guid isPermaLink="false">4292@http://www.pharmaphorum.com/forums/</guid>
<description>&#60;p&#62;Lilly Reports Fourth-Quarter and Full-Year 2011 Results Fourth quarter revenue declined two percent driven by Zyprexa and Gemzar patent...&#60;/p&#62;
&#60;p&#62;Source: Reuters&#60;/p&#62;
&#60;p&#62;&#60;a href=&#34;https://newsdesk4.moreover.com/click/?p=lhxtxtxezambmblzm6l8lbxml2lbxll2xmm6lzlbl8mblzlklnlzljmblhl2xml2m6xelkzbxaz2zhztzezozxzeztzezxmlxaz8zozmz2zezmztzhzlzxzl&#38;amp;a=z2zhztzezozxzeztzezx&#38;amp;f=t6l2xxxz&#38;amp;s=lll2l2lt&#38;amp;u=xelox2lktexelhloxml8loxelhlbxmx2l8m6lzlbl8&#38;amp;c=2elhloxml8lometllbxmx2l8&#38;amp;i=ze&#34; target=&#34;_blank&#34;&#62;https://newsdesk4.mo...etllbxmx2l8&#38;amp;i=ze&#60;/a&#62;
&#60;/p&#62;</description>
</item>

</channel>
</rss>

